Current concepts and perspectives of immunosuppression in organ transplantation

被引:32
作者
Scherer, Marcus N.
Banas, Bernhard
Mantouvalou, Kiriaki
Schnitzbauer, Andreas
Obed, Aiman
Kraemer, Bernhard K.
Schlitt, Hans J.
机构
[1] Klinikum Univ Regensburg, Klin & Poliklin Chirurg & Transplantat, D-93042 Regensburg, Germany
[2] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany
关键词
individually tailored immunosuppression; drug-related side effects; calcineurin-inhibitor-sparing; steroid-avoidance; mTOR inhibitor; impaired renal function; de-novo/recurrence of cancer; true/prope tolerance;
D O I
10.1007/s00423-007-0188-z
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background While early surgical success made organ transplantation possible in the 1950s and 1960s, the breakthrough in clinical organ transplantation was achieved through the discovery and invention of modern immunosuppressive agents in the early/mid-1980s. Especially during the 1990s, a large array of immunosuppressants has expanded the armamentarium used to prevent and treat allograft rejection, resulting in an excellent short-term and an acceptable long-term outcome. However, these drugs have potent but still non-specific immunosuppressive properties and frequently show severe acute and chronic side effects, sometimes questioning the overall success. Concepts/Trends As the "Holy-Grail" of the transplant community, the induction of "true donor-specific tolerance" has not been achieved yet; current immunosuppressive strategies, in particular in Europe, include "individually tailored immunosuppressive" protocols, mostly based on specific immunologic and non-immunologic risk factors. These protocols allow for optimal immunosuppressive protocols for each patient group according to their needs by choosing the most suitable, well-tolerated combination of agents and the most effective doses to avoid acute rejection episodes (incidence and severity) and minimise drug-related toxicity to reduce long-term drug-related morbidity and mortality. Nevertheless, transplant recipient are still being forced to take a life-long course of chemical immunosuppressive agents to keep their graft, knowing about the possible life-threatening side effects. Summary We review current trends of immunosuppressive protocols in liver and kidney transplantation, focusing on calcineurin-inhibitor-sparing protocols, mammalian-target-of-rapamycin (mTOR) inhibitor based-protocols and corticosteroid-avoidance protocols, being aware of the fact, that most of these strategies could be applicable for other transplanted organs, too. Finally, we describe future trends and new developments that are rising on the horizon.
引用
收藏
页码:511 / 523
页数:13
相关论文
共 101 条
  • [1] Cancer risk following organ transplantation:: a nationwide cohort study in Sweden
    Adami, J
    Gäbel, H
    Lindelöf, B
    Ekström, K
    Rydh, B
    Glimelius, B
    Ekbom, A
    Adami, HO
    Granath, F
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (07) : 1221 - 1227
  • [2] Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival
    Adams, AB
    Shirasugi, N
    Jones, TR
    Durham, MM
    Strobert, EA
    Cowan, S
    Rees, P
    Hendrix, R
    Price, K
    Kenyon, NS
    Hagerty, D
    Townsend, R
    Hollenbaugh, D
    Pearson, TC
    Larsen, CP
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (01) : 542 - 550
  • [3] Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
    Asberg, Anders
    Midtvedt, Karsten
    Line, Pal D.
    Narverud, Janicke
    Holdaas, Hallvard
    Jenssen, Trond
    Reisaeter, Anna V.
    Johnsen, Linda F.
    Fauchald, Per
    Hartmann, Anders
    [J]. TRANSPLANTATION, 2006, 82 (01) : 62 - 68
  • [4] Is clinical tolerance realistic in the next decade?
    Ashton-Chess, Joanna
    Brouard, Sophie
    Soulillou, Jean-Paul
    [J]. TRANSPLANT INTERNATIONAL, 2006, 19 (07) : 539 - 548
  • [5] Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil
    Barkmann, A
    Nashan, B
    Schmidt, HHJ
    Böker, KHW
    Emmanouilidis, N
    Rosenau, J
    Bahr, MJ
    Hoffmann, MW
    Manns, MP
    Klempnauer, J
    Schlitt, HJ
    [J]. TRANSPLANTATION, 2000, 69 (09) : 1886 - 1890
  • [6] Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation
    Barth, Rolf N.
    Janus, Christina A.
    Lillesand, Christine A.
    Radke, Nancy A.
    Pirsch, John D.
    Becker, Bryan N.
    Fernandez, Luis A.
    Chin, L. Thomas
    Becker, Yolanda T.
    Odorico, Jon S.
    D'Alessandro, Anthony M.
    Sollinger, Hans W.
    Knechtle, Stuart J.
    [J]. TRANSPLANT INTERNATIONAL, 2006, 19 (11) : 885 - 892
  • [7] BENSELER V, 2007, IN PRESS SEMIN LIVER
  • [8] Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression
    Berenguer, M
    Aguilera, V
    Prieto, M
    San Juan, F
    Rayón, JM
    Benlloch, S
    Berenguer, J
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (04) : 717 - 722
  • [9] T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients
    Bloom, DD
    Hu, HZ
    Fechner, JH
    Knechtle, SJ
    [J]. TRANSPLANTATION, 2006, 81 (01) : 81 - 87
  • [10] Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: A large randomized clinical study
    Boillot, O
    Mayer, DA
    Boudjema, K
    Salizzoni, M
    Gridelli, B
    Filipponi, F
    Trunecka, P
    Krawczyk, M
    Clavien, PA
    Ducerf, C
    Margarit, C
    Margreiter, R
    Pallardo, JM
    Hoeckerstedt, K
    Pageaux, GP
    [J]. LIVER TRANSPLANTATION, 2005, 11 (01) : 61 - 67